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Abstract
Background: Prior studies using creatinine-based estimated glomerular filtration rate (eGFR)
have found limited associations between kidney function and markers of inflammation. Using eGFR
and cystatin C, a novel marker of kidney function, the authors investigated the association of kidney
function with multiple biomarkers in a diverse cohort.
Methods: The Multi-Ethnic Study of Atherosclerosis consists of 6,814 participants of white,
African-American, Hispanic, and Chinese descent, enrolled from 2000–2002 from six U.S.
communities. Measurements at the enrollment visit included serum creatinine, cystatin C, and six
inflammatory and procoagulant biomarkers. Creatinine-based eGFR was estimated using the four-
variable Modification of Diet in Renal Disease equation, and chronic kidney disease was defined by
an eGFR < 60 mL/min/1.73 m2.
Results: Adjusted partial correlations between cystatin C and all biomarkers were statistically
significant: C-reactive protein (r = 0.08), interleukin-6 (r = 0.16), tumor necrosis factor-α soluble
receptor 1 (TNF-αR1; r = 0.75), intercellular adhesion molecule-1 (r = 0.21), fibrinogen (r = 0.14),
and factor VIII (r = 0.11; two-sided p < 0.01 for all). In participants without chronic kidney disease,
higher creatinine-based eGFR was associated only with higher TNF-αR1 levels.
Conclusion: In a cohort characterized by ethnic diversity, cystatin C was directly associated with
multiple procoagulant and inflammatory markers. Creatinine-based eGFR had similar associations
with these biomarkers among subjects with chronic kidney disease.
Background
Higher levels of markers of inflammation, such as C-reac-
tive protein (CRP) and interleukin 6 (IL-6), have been
associated with cardiovascular disease in healthy popula-
tions [1-3]. In subjects with end stage renal disease
(ESRD), inflammatory biomarkers are significantly ele-
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vated and predict poor outcomes [4-7]. In subjects with
kidney disease not on hemodialysis, kidney function has
been associated with markers of inflammation for creati-
nine-based estimated glomerular filtration rates (eGFR)
below 60 mL/min/1.73 m2. Above that threshold, two
studies did not find an association between eGFR and
markers of inflammation [8,9].
Cystatin C, a cysteine protease inhibitor secreted by all
nucleated cells, is a novel serum marker for kidney disease
that may better detect small changes in kidney function
[10-12]. Since creatinine-based eGFR is not reliable above
60 mL/min/1.73 m2, cystatin C may be superior in detect-
ing an association with inflammation in subjects with
mild to moderate kidney disease [13,14]. Using cystatin C
as a marker for kidney function in an ambulatory elderly
cohort, all with creatinine-based eGFR ≥ 60, we reported
linear associations between cystatin C and five inflamma-
tory markers: CRP, IL-6, tumor necrosis factor alpha (TNF-
α), and two soluble TNF-α receptors [15]. In a cohort with
known coronary artery disease, cystatin C was associated
with both CRP and fibrinogen across the entire cohort,
while creatinine-based eGFR was significantly associated
with CRP and fibrinogen only for eGFR < 60 [16].
The current study investigated the association of both cre-
atinine-based eGFR and cystatin C with six inflammatory
and procoagulant biomarkers in the Multi-Ethnic Study of
Atherosclerosis (MESA), a large cohort characterized by
racial and ethnic diversity. Compared with prior studies
on kidney function and markers of inflammation, this
study featured a population with four racial/ethnic
groups, a younger mean age (62 years), no clinical cardio-
vascular disease, and more extensive measurements of
both inflammatory and procoagulant biomarkers. In
addition, a second objective of this study was to test
whether the association between kidney function and
multiple inflammatory and procoagulant biomarkers dif-
fered by race/ethnicity.
Methods
The MESA cohort consists of 6,814 men and women who
identified themselves as white, African-American, His-
panic, or Asian (of Chinese descent). At the time of enroll-
ment, the subjects were 45 to 84 years of age and free of
clinical cardiovascular disease (CVD). Participants were
enrolled from July 2000 to August 2002, and recruited
from six US communities. Subjects were initially recruited
using residential and telephone listings; towards the end
of the recruitment period, lists of Medicare beneficiaries
and participant referrals were also used to ensure an ade-
quate number of participants. The study was approved by
institutional review boards at each center, and all study
participants gave informed consent.
All biochemistry assays were performed on plasma or
serum drawn in the morning after an overnight fast during
the initial visit and stored at -70°C. Cystatin C was meas-
ured using a BNII nephelometer on plasma specimens (N
Latex Cystatin C; Dade Behring Inc., Deerfield, IL) [17].
The assay range is 0.195 to 7.330 mg/L, with the reference
range for young, healthy individuals reported as 0.53 –
0.95 mg/L. Intra-assay coefficients of variation (CVs)
range from 2.0 – 2.8% and inter-assay CVs range from 2.3
– 3.1%. Serum creatinine was measured using colorimetry
with a Johnson & Johnson Vitros 950 analyzer (Johnson
& Johnson Clinical Diagnostics Inc., Rochester, NY). The
CVs for serum creatinine were ≤ 2%. Estimated GFR was
calculated using the creatinine-based four-variable Modi-
fication of Diet in Renal Disease (MDRD) equation,
which features adjustments for age, gender, serum creati-
nine, and black race [18]. Creatinine levels were calibrated
to the Cleveland Clinic standard (0.9954*Cr + 0.0208)
[19]. Lipid measurements were performed using the
Roche COBAS FARA centrifugal analyzer (Roche Diagnos-
tics, Indianapolis, IN). Low-density lipoprotein choles-
terol (LDL) was calculated using the Friedewald equation
[20]. Serum glucose was measured using the Vitros 950
analyzer. Urine samples for measuring creatinine and
albumin were taken from a spot urine collection at the ini-
tial visit. Urinary creatinine was measured using the Vitros
950. Urinary albumin was measured using an Array 360
CE Protein Analyzer (Beckman Instruments Inc., Fuller-
ton, CA). Chronic kidney disease was defined as eGFR <
60 mL/min/1.73 m2[13].
CRP was measured using a BNII nephelometer (N high
sensitivity CRP; Dade Behring Inc.), with intra-assay CVs
of 2.3% – 4.4%, inter-assay CVs of 2.1% – 5.7%, and a
detection level of 0.18 mg/L [21]. IL-6 was measured by
ultra-sensitive ELISA (Quantikine HS Human IL-6 Immu-
noassay; R&D Systems, Minneapolis, MN) with an analyt-
ical CV of 6.3% and a detection level of 0.04 pg/mL.
Tumor necrosis factor alpha receptor 1 (TNF-αR1) was
measured by ultra-sensitive ELISA (Quantikine Human
sTNF RI Immunoassay; R&D Systems) with an analytical
CV of 5.0% and a detection level of 0.77 pg/mL. Intercel-
lular adhesion molecule 1 (ICAM-1) was measured by
ELISA (Parameter Human sICAM-1 Immunoassay; R&D
Systems), with a CV of 5.0%. Fibrinogen was measured
using a BNII nephelometer (N Antiserum to Human
Fibrinogen; Dade Behring Inc.) with intra-assay and inter-
assay analytical CVs of 2.7% and 2.6%, respectively. Fac-
tor VIII coagulant activity was determined by measuring
the clotting time of a sample in factor VIII deficient
plasma in the presence of activators utilizing the Sta-R
analyzer (STA-Deficient VIII; Diagnostica Stago, Parsip-
pany, NJ), with a reported normal plasma range in the
adult population of 60–150%. CRP, IL-6, fibrinogen, and
factor VIII were measured in the entire cohort. Intercellu-BMC Nephrology 2008, 9:9 http://www.biomedcentral.com/1471-2369/9/9
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lar adhesion molecule-1 (ICAM-1) was measured in a
total of 2,614 subjects, including all participants who
enrolled before February 2003 and a subset of 1,000 par-
ticipants randomly selected from the first 5,030 partici-
pants enrolled. The baseline characteristics of the random
subset of participants were not significantly different from
those of the entire MESA cohort. TNF-αR1 (995 samples)
was measured in a subset of the cohort chosen randomly
after 75% of the participants had been enrolled.
Participant characteristics, including demographics (age,
sex, race/ethnicity); comorbid conditions (diabetes,
defined as a fasting glucose ≥ 126 mg/dL (6.9 mmol/L) or
by the use of insulin or oral hypoglycemic medications,
and hypertension, defined as an average systolic blood
pressure ≥ 140 mm Hg, an average diastolic blood pres-
sure of ≥ 90 mm Hg, or by the use of antihypertensive
medications), smoking history, defined as ever [current or
former] or never; and statin use were obtained at the
enrollment visit using data from standardized question-
naires. Resting blood pressure was determined by taking
three measurements with the participant in the seated
position; systolic and diastolic blood pressures were
recorded as the average value of the last two measure-
ments from both the first and second study examinations.
Body mass index (BMI) was calculated at the initial visit
using weight (kg) divided by height squared (m2).
Statistical Analysis
Baseline characteristics were evaluated for statistical sig-
nificance across quintiles of cystatin C using ANOVA or
chi-square tests for trend. Histograms and q-q plots
revealed that the urinary albumin to creatinine ratio and
the levels of CRP and IL-6 were skewed; therefore, loga-
rithmic transformations of these variables were used for
analysis. First, partial correlations with each of the six
biomarkers were determined separately for cystatin C and
creatinine-based eGFR, adjusting for age, gender, race/eth-
nicity, and BMI. Two-tailed t-tests were used for signifi-
cance testing of all partial correlations. We also compared
the partial correlation coefficients of eGFR and cystatin C
with each biomarker after stratification by presence or
absence of CKD. The two correlation coefficients were
transformed using the Fisher Z-transform and the differ-
ence and a p-value were computed.
We created separate linear regression models for each of
the six biomarkers. The primary predictors were either
cystatin C (per SD) or eGFR by the four-variable MDRD
equation, dichotomized as < and ≥ 60 ml/min/1.73 m2.
Covariates from Table 1 were entered into the models
based on their potential role as confounders due to their
associations with both kidney disease and inflammation.
We also determined the adjusted mean levels of each
biomarker, stratified by the presence of CKD (eGFR < 60
mL/min/1.73 m2) and by quintile of cystatin C. The mean
biomarker levels were also plotted across quintiles of
cystatin C, with the y-axis scale standardized at ± 1 SD of
the overall mean of the cohort for each biomarker. For
TNF-αR1, the y-axis scale was set at ± 2 SD given the larger
differences for that biomarker across quintiles of cystatin
C. T-tests were used to evaluate significant differences in
mean levels in subjects with and without CKD, and
ANOVA across quintiles of cystatin C. We also tested for
interactions of race/ethnicity with both cystatin C in each
regression model. S-Plus (release 6.1, Insightful Inc, Seat-
tle, WA) and SPSS statistical software (release 13.0.1, SPSS
Inc, Chicago, IL) were used for the analyses. P < 0.01 was
used for statistical significance because multiple compari-
sons were made and because a high level of power was
available.
Results
The participants of the MESA study had an average age of
62 years. In the cohort, 53% of the participants were
female; 39% were white, 28% African-American, 22%
Hispanic, and 12% Chinese. The mean cystatin C level in
the cohort was 0.89 ± 0.24 mg/L, and the mean creatinine-
based eGFR was 81 ± 18 mL/min/1.73 m2. On average,
the participants in the highest quintile of cystatin C were
older, and more likely white and male (Table 1). Those in
the highest quintile were also more likely to smoke, to
have hypertension and diabetes, to have a higher BMI, to
have a higher urine albumin to creatinine ratio, and to
have lower levels of both LDL and HDL. Overall, the total
number of subjects with CKD in the cohort was 672
(10%).
After adjustment for age, sex, ethnicity, and BMI, cystatin
C had statistically significant partial correlations with all
six biomarkers in participants both with and without CKD
(Table 2, p < 0.01 for all). However, the associations with
TNF-αR1 and fibrinogen were significantly stronger
among participants with CKD. Similarly, creatinine-based
eGFR had significant correlations with all biomarkers
except ICAM-1 in subjects with CKD (p < 0.01). In sub-
jects without CKD, eGFR was associated only with TNF-
αR1. Of note, the strongest correlations for both cystatin
C and creatinine-based eGFR were with TNF-αR1.
Adjusted mean levels of all biomarkers except ICAM-1
were significantly higher in participants with CKD (eGFR
< 60) than in those without CKD (Table 3; p < 0.001 for
all). The mean levels of each biomarker in subjects with-
out CKD were unchanged by adjustment for albumin to
creatinine ratio. Adjusted mean levels for all six biomark-
ers increased significantly across the five quintiles of cysta-
tin C (Figures 1a–c). The p-values for trend of the mean
biomarker levels across all quintiles were less than 0.01.
For comparison, we found that the mean biomarker levelsBMC Nephrology 2008, 9:9 http://www.biomedcentral.com/1471-2369/9/9
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among persons with CKD were similar to the highest
quintile of cystatin C in the entire cohort. Finally, adjusted
linear regression models using cystatin C to predict
biomarker levels were also examined for interactions by
race/ethnicity. Statistically significant race/ethnicity inter-
actions were found for the associations of cystatin C with
CRP, IL-6, ICAM-1, and factor VIII (Table 4).
Discussion
Our analysis demonstrated that cystatin C was signifi-
cantly correlated with all six procoagulant and inflamma-
tory biomarkers across a broad range of kidney function,
even after adjustment for age, gender, race/ethnicity, and
BMI. While creatinine-based eGFR had significant correla-
tions with all biomarkers except ICAM-1 in subjects with
CKD, it was only associated with TNF-αR1 in participants
without CKD. Adjusted mean levels of all biomarkers
increased significantly across each quintile of cystatin C,
and all biomarkers except ICAM-1 were elevated in per-
sons with eGFR < 60 compared with eGFR ≥ 60. In gen-
eral, TNF-αR1 had the strongest correlations with both
cystatin C and eGFR in all groups.
Both creatinine-based eGFR and cystatin C correlated with
most inflammatory markers in subjects with chronic kid-
ney disease. However, in patients without CKD, only
cystatin C had significant correlations with all markers of
inflammation. There are several possible explanations for
the association of cystatin C with procoagulant and
inflammatory biomarkers in patients without chronic kid-
ney disease. One possibility is that GFR is linearly associ-
ated with inflammation, and using cystatin C, a marker of
renal function that is less dependent on muscle mass or
age, reveals the true association between kidney function
and markers of inflammation when GFR is greater than 60
mL/min/1.73 m2[22]. Prior studies have shown that
inflammatory markers are not associated with creatinine-
based eGFR above 60 [8,9,16]. However, this absence of
association may be due to imprecision of eGFR in the nor-
mal range. A second explanation is that cystatin C is asso-
ciated with inflammation independent of kidney function
[23,24]. One study found that cystatin C was associated
with CRP independent of creatinine clearance; however,
that study did not have the gold standard of measured
GFR [25]. Another study, also without a gold standard for
GFR, found that the association between cystatin C and
Table 1: Baseline characteristics of MESA population by quintiles of cystatin C
Cystatin C (mg/L)
Quintile 1  Quintile 2 Quintile 3 Quintile 4 Quintile 5
≤ 0.74 0.75–0.82 0.83–0.89 0.91–1.02 ≥ 1.03
(n = 1446) (n = 1377) (n = 1283) (n = 1359) (n = 1285)
Mean ± SD, Median [IQR], or % p-value for trend
Age 57 ± 9 59 ± 9 62 ± 9 65 ± 10 69 ± 10 <0.001
Female, % 65 53 49 47 49 <0.001
Race/Ethnicity, %
W h i t e 3 33 4 4 14 1 4 4
Chinese 17 13 10 11 8
African-American 30 30 26 24 28
Hispanic 19 24 23 24 20
Smoking History, % 44 49 50 53 53 <0.001
BMI (kg/m2) 27 ± 5 28 ± 5 28 ± 5 29 ± 6 30 ± 6 <0.001
Diabetes, % 14 13 12 12 21 <0.001
H y p e r t e n s i o n ,  % 3 43 6 4 35 0 6 4< 0 . 0 0 1
LDL (mg/dL) 117 ± 32 119 ± 31 118 ± 31 117 ± 32 114 ± 32 0.006
HDL (mg/dL) 56 ± 16 51 ± 15 51 ± 14 49 ± 14 48 ± 14 <0.001
Glucose (mg/dL) 105 ± 37 104 ± 32 102 ± 22 104 ± 28 107 ± 31 0.128
Medication use, %
ACE-inhibitors 0.6 0.9 0.9 1.5 1.9 0.005
Beta-blockers 0.3 0.4 0.9 0.7 0.5 0.427
Statin use 11 14 15 16 19 <0.001
Urinary albumin/creatinine ratio (mg/g) 5.1 [3.4, 10.3] 5.1 [3.2, 9.5] 5.1 [3.1, 9.0] 5.3 [3.3, 10.7] 7.4 [3.9, 20.0] <0.001
Serum cystatin C (mg/L) 0.68 ± 0.06 0.77 ± 0.02 0.86 ± 0.02 0.96 ± 0.03 1.22 ± 0.36 <0.001
Creatinine-based eGFR (ml/min/1.73 m2) 93 ± 16 87 ± 15 82 ± 19 77 ± 13 65 ± 16 <0.001
To convert LDL or HDL from mg/dL to mmol/L, divide by 39; to convert glucose, divide by 18; to convert urinary albumin/creatinine ratio from mg/
g to mg/mmol, multiply by 0.114; to convert serum creatinine from mg/dL to μmol/L, multiply by 88.BMC Nephrology 2008, 9:9 http://www.biomedcentral.com/1471-2369/9/9
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CRP disappeared after adjustment for 24-hour urine creat-
inine clearance [16]. Our observation in this current
study, that creatinine-based eGFR and cystatin C have
similar associations with inflammatory markers among
persons with CKD, makes it seem less likely that cystatin
C has a direct association with inflammation that is inde-
pendent of kidney function. However, our study also lacks
a gold standard measurement of GFR, and therefore can-
not be conclusive.
Both cystatin C and eGFR had substantial correlations
with TNF-αR1, while the associations with the other
inflammatory and procoagulant markers were more mod-
est. In a murine model, one study demonstrated that 125I-
labeled soluble TNF receptors were primarily cleared by
the mouse kidney [26]. In contrast, other inflammatory
markers, such as CRP and IL-6, are primarily cleared by
the liver [27,28]. While the strong association between
kidney function and TNF-αR1 levels may be simply attrib-
utable to renal clearance of TNF-αR1, TNF-α itself may
also play a more complex role in the mediation of kidney
damage. A future study should evaluate whether TNF-α
and its soluble receptors predict the longitudinal progres-
sion of kidney disease.
A secondary goal of our analysis was to assess the role of
race/ethnicity in the association between cystatin C and
markers of inflammation. The association of four biomar-
kers – CRP, IL-6, ICAM-1, and factor VIII – with cystatin C
had statistically significant interactions by race/ethnicity.
Specifically, these four biomarkers had higher beta coeffi-
cients in whites compared with other races/ethnicities.
One important issue is that, according to recent data, the
assay used in MESA is only able to detect certain polymor-
phisms of ICAM-1 [29]. One allele in particular, ICAM-1
RS5491-T, is more common in African-Americans and not
detected by the MESA assay. Further research is ongoing to
evaluate the importance of polymorphisms on detection
Table 3: Adjusted mean biomarker levels at the baseline visit of the MESA study, in participants with and without chronic kidney 
disease
Biomarker (units) CKD Mean levels (95% CI) No CKD Mean levels (95% CI) P-value
CRP (log mg/L) N = 6750 0.81 (0.73, 0.89) 0.63 (0.61, 0.66) <0.001
IL-6 (log pg/mL) N = 6622 0.37 (0.33, 0.41) 0.19 (0.18, 0.21) <0.001
TNF-αR1 (pg/mL) N = 995 1.90 (1.76, 2.03) 1.23 (1.22, 1.25) <0.001
ICAM-1 (ng/mL) N = 2611 281 (271, 290) 274 (271, 277) 0.19
Fibrinogen (mg/dL) N = 6750 363 (360, 372) 345 (343, 346) <0.001
Factor VIII (%) N = 6750 187 (181, 193) 161 (160, 163) <0.001
All biomarker models adjusted for age, gender, race/ethnicity, smoking status, BMI, diabetes, hypertension, LDL, HDL, and use of statins
Chronic kidney disease (CKD) defined as eGFR < 60 mL/min/1.73 m2
Table 2: Partial correlations of cystatin C and creatinine-based eGFR with inflammatory and procoagulant markers at the baseline visit 
of the MESA study, stratified by presence of chronic kidney disease
Marker of Kidney Function Inflammatory Marker
CRP 
(N = 6750)
IL-6 
(N = 6622)
TNF-αR1 
(N = 995)
ICAM-1 
(N = 2611)
Fibrinogen 
(N = 6750)
Factor VIII 
(N = 6750)
Cystatin C 0.075* 0.156* 0.748* 0.209* 0.137* 0.112*
Creatinine-based eGFR -0.019 -0.003 -0.285* 0.025 -0.059* -0.034*
Persons with CKD
Cystatin C 0.116* 0.230* 0.903* 0.160* 0.248* 0.140*
Creatinine-based eGFR -0.101* -0.139* -0.763* -0.035 -0.286* -0.146*
Persons without CKD
Cystatin C 0.085* 0.180* 0.557*† 0.261* 0.111*† 0.085*
Creatinine-based eGFR -0.004‡ 0.025‡ -0.168*‡ 0.027 -0.021‡ 0.017‡
Partial correlations adjusted for age, gender, race/ethnicity, and BMI
Chronic kidney disease (CKD) defined as eGFR < 60 mL/min/1.73 m2
* Correlation is significant at the 0.01 level (2-tailed).
† Correlation between cystatin C and the biomarker is significantly stronger among participants with CKD
‡ Correlation between creatinine-based eGFR and the biomarker is significantly stronger among participants with CKDBMC Nephrology 2008, 9:9 http://www.biomedcentral.com/1471-2369/9/9
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of circulating markers of inflammation. In the MESA
study, we are not aware of other assay issues that would
affect the interpretation of race/ethnicity interactions with
biomarkers.
One possible explanation for the interactions by race/eth-
nicity in cystatin C models is that regulation of inflamma-
tory cytokines is more dependent on intact kidney
function in whites than in other races/ethnicities. Prior
studies have shown that CRP and fibrinogen levels are
lower in whites than in African-Americans, and that
whites at a given baseline level of CRP seem to have
slower rises in serum creatinine over time compared with
African-Americans [30-32]. These findings would suggest
that whites may have a propensity for greater renal excre-
tion of cytokines, although additional studies using urine
measurements of cytokines may be helpful to evaluate
these associations more effectively. Another explanation
for these findings is that cystatin C is a better marker of
GFR in whites versus other races/ethnicities. Overall, the
association of cystatin C with GFR in non-white groups
has not been well studied.
Our analysis has several limitations. First, while cystatin C
has been conclusively demonstrated to be a reliable
marker of kidney function, it may have associations with
inflammation that are dependent of kidney function.
Such associations would not be supported by this study,
however, since we found that cystatin C and creatinine-
based eGFR had equally strong associations with inflam-
matory markers for subjects when eGFR < 60. Second, as
a cross-sectional study, we are unable to determine tem-
porality in the association between cystatin C and multi-
ple biomarkers. For example, inflammation may lead to
declining kidney function, or reduced kidney function
may lead to elevated inflammatory biomarkers. As stated
above, we did not have a gold standard measurement for
kidney function, such as iothalamate clearance. We also
assumed that eGFR < 60 was the appropriate cutpoint for
chronic kidney disease for all subjects, although some
data suggests that the established MDRD equation may
need to be modified to more accurately characterize CKD
race/ethnicity groups other than whites and African-
Americans [33].
Conclusion
We report significant associations between kidney dys-
function and markers of inflammation and procoagula-
tion in a diverse population. Using cystatin C,
associations were present in those with and without
chronic kidney disease. Creatinine-based eGFR was simi-
larly associated with these biomarkers primarily among
subjects with CKD. These results suggest that markers of
inflammation are progressively elevated as kidney func-
tion declines, even in subjects without chronic kidney dis-
ease.
Adjusted mean biomarkers by quintiles of cystatin C at the  baseline visit of the MESA study Figure 1
Adjusted mean biomarkers by quintiles of cystatin C 
at the baseline visit of the MESA study. Models adjusted 
for age, gender, race/ethnicity, smoking status, body mass 
index, diabetes, hypertension, low-density lipoprotein, high-
density lipoprotein, use of statins, and log transformed uri-
nary albumin to creatinine ratio. Y-axis scales are standard-
ized to ± 2 standard deviations of the overall mean of the 
cohort for TNF-αR1 and ± 1 standard deviation of the over-
all mean of the cohort for all other biomarkers.
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